A. Z. S. Rohatiner - Concepedia

Author

A. Z. S. Rohatiner

Also Known As

A ROHATINER, A Rohatiner, A Z Rohatiner, A Z S Rohatiner, A. Rohatiner, A. Z. S. ROHATINER, A. Z. S. Rohatiner, A. Z.S. Rohatiner, A. Zs Rohatiner, A.Z.S. Rohatiner

154

Publications

9.3K

Citations

H-Index

Concepts

All Affiliations

St Bartholomew's Hospital Cancer Research UK The Christie Hospital University College London Institute of Cancer Research

About

A. Z. S. Rohatiner is an author at St Bartholomew's Hospital specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	30	2.3K
2	Health Sciences	11	11	951
3	Natural Sciences	1	1	303
4	Biochemistry	1	1	303
5	Cell Biology	1	1	303

A. Z. S. Rohatiner

Publications

8.6K

Citations

H-Index

Page 1

	Year	Citations
European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma James M. Foran, A. Z. S. Rohatiner, David Cunningham, Journal of Clinical Oncology	2000	471
Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma Franck Morschhauser, John Radford, Achiel Van Hoof, Journal of Clinical Oncology	2008	458
Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study Anthony J. Swerdlow, Craig Higgins, Paul Smith, JNCI Journal of the National Cancer Institute	2007	444
Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Silvia Montoto, Andrew Davies, Janet Matthews, Journal of Clinical Oncology	2007	387
Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas Julie M. Vose, Richard L. Wahl, Mansoor N. Saleh, Journal of Clinical Oncology	2000	360
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman, Journal of Clinical Oncology Novel ImmunoconjugateImmunologyPharmacotherapyMetronomic ChemotherapyRefractory Cd22	2010	329
Characterization of Cells with a High Aldehyde Dehydrogenase Activity from Cord Blood and Acute Myeloid Leukemia Samples Daniel J. Pearce, David Taussig, Catherine Simpson, Stem Cells Mixed-phenotype Acute LeukemiaPathologyRedox BiologyOxidative StressMyeloid Neoplasia	2005	303
Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis Monica Else, Claire Dearden, Estella Matutes, British Journal of Haematology	2009	264
Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. A. Z. S. Rohatiner, Peter Johnson, C. G. A. Price, Journal of Clinical Oncology	1994	234
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML Daniel J. Pearce, David Taussig, Kazem Zibara, Blood	2005	233

Page 1